Ipca Laboratories approves amalgamation with Krebs Biochemicals
Ipca Laboratories approved the amalgamation of Krebs Biochemicals & Industries Ltd to secure fermentation-based API supplies and intermediates. The Board approved the scheme on June 26, 2026, with an appointed date of April 1, 2026. The merger involves a share exchange ratio of 7 equity shares of Ipca for every 200 shares of Krebs, with no cash consideration.
*this image is generated using AI for illustrative purposes only.
Ipca Laboratories Ltd approved the amalgamation of Krebs Biochemicals & Industries Ltd with itself to secure the supply of critical fermentation-based Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Board of Directors approved the Scheme of Amalgamation on June 26, 2026, under Sections 230 to 232 of the Companies Act, 2013. The Appointed Date for the scheme is April 1, 2026, and it will become effective upon receiving necessary consents from regulatory authorities, including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The transaction is classified as a related party transaction conducted at arm’s length. Both entities are engaged in the manufacturing and marketing of pharmaceuticals. For the financial year ended March 31, 2026, Ipca Laboratories reported a standalone audited total income of ₹7431 Crores, while Krebs Biochemicals reported an audited total income of ₹26 Crores, primarily derived from conversion charges received from Ipca Laboratories.
Rationale for the Merger
The Board outlined several strategic reasons for the amalgamation. Krebs Biochemicals possesses the capability and manufacturing facility to produce fermentation-based APIs, a capacity Ipca Laboratories currently lacks. The merger will enable Ipca to research, develop, and commercialize new fermentation-based APIs. Additionally, Krebs produces a fermentation-based API used as a therapeutic ingredient in Ipca’s largest-selling formulation and manufactures drug intermediates used by Ipca for key APIs. The scheme ensures an uninterrupted supply of these critical materials. Krebs Biochemicals has been incurring losses and the merger is expected to facilitate research and development spending through Ipca's financial strength and technical capabilities.
Share Exchange Ratio
The scheme involves no cash consideration. Ipca Laboratories will issue and allot 7 fully paid-up equity shares of Re. 1 each for every 200 fully paid-up equity shares of Rs. 10 each held in Krebs Biochemicals. Equity and preference shares held by Ipca in Krebs will be cancelled and extinguished without any consideration. Consequently, the promoter shareholding in the amalgamated company will decrease, while public shareholding will increase.
Shareholding Pattern
The amalgamation will alter the shareholding pattern of Ipca Laboratories. The total number of shares will increase from 25,37,04,218 to 25,40,84,157.
| Category | Pre-Scheme Shares | Pre-Scheme % | Post-Scheme Shares | Post-Scheme % |
|---|---|---|---|---|
| Promoters | 11,34,67,472 | 44.72% | 11,34,67,472 | 44.66% |
| Public | 14,02,36,746 | 55.28% | 14,06,16,685 | 55.34% |
| Total | 25,37,04,218 | 100.00% | 25,40,84,157 | 100.00% |
Historical Stock Returns for IPCA Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.85% | -6.47% | +9.65% | +22.18% | +15.37% | +59.72% |
How will the absorption of Krebs Biochemicals' accumulated losses impact Ipca Laboratories' consolidated tax liabilities in the coming fiscal years?
What specific timeline does Ipca anticipate for the regulatory approval process, and are there any anticipated hurdles from SEBI or competition authorities?
Will the merger trigger any significant restructuring costs or integration expenses that could affect Ipca's short-term profitability?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
